
- 要闻
- 廉价购买康基医疗控股有限公司(HKG: 9997)不太可能
Getting In Cheap On Kangji Medical Holdings Limited (HKG:9997) Is Unlikely
Getting In Cheap On Kangji Medical Holdings Limited (HKG:9997) Is Unlikely
When close to half the companies in Hong Kong have price-to-earnings ratios (or "P/E's") below 9x, you may consider Kangji Medical Holdings Limited (HKG:9997) as a stock to potentially avoid with its 13.4x P/E ratio. Nonetheless, we'd need to dig a little deeper to determine if there is a rational basis for the elevated P/E.
Recent times have been pleasing for Kangji Medical Holdings as its earnings have risen in spite of the market's earnings going into reverse. The P/E is probably high because investors think the company will continue to navigate the broader market headwinds better than most. If not, then existing shareholders might be a little nervous about the viability of the share price.
See our latest analysis for Kangji Medical Holdings

Does Growth Match The High P/E?
In order to justify its P/E ratio, Kangji Medical Holdings would need to produce impressive growth in excess of the market.
Taking a look back first, we see that the company grew earnings per share by an impressive 43% last year. The latest three year period has also seen an excellent 98% overall rise in EPS, aided by its short-term performance. Accordingly, shareholders would have probably welcomed those medium-term rates of earnings growth.
Turning to the outlook, the next three years should generate growth of 8.9% per annum as estimated by the dual analysts watching the company. Meanwhile, the rest of the market is forecast to expand by 16% per year, which is noticeably more attractive.
In light of this, it's alarming that Kangji Medical Holdings' P/E sits above the majority of other companies. Apparently many investors in the company are way more bullish than analysts indicate and aren't willing to let go of their stock at any price. There's a good chance these shareholders are setting themselves up for future disappointment if the P/E falls to levels more in line with the growth outlook.
The Bottom Line On Kangji Medical Holdings' P/E
Typically, we'd caution against reading too much into price-to-earnings ratios when settling on investment decisions, though it can reveal plenty about what other market participants think about the company.
Our examination of Kangji Medical Holdings' analyst forecasts revealed that its inferior earnings outlook isn't impacting its high P/E anywhere near as much as we would have predicted. When we see a weak earnings outlook with slower than market growth, we suspect the share price is at risk of declining, sending the high P/E lower. This places shareholders' investments at significant risk and potential investors in danger of paying an excessive premium.
Don't forget that there may be other risks. For instance, we've identified 1 warning sign for Kangji Medical Holdings that you should be aware of.
If P/E ratios interest you, you may wish to see this free collection of other companies with strong earnings growth and low P/E ratios.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
当将近一半的香港公司的市盈率(或 “市盈率”)低于9倍时,您可以将康基医疗控股有限公司(HKG: 9997)视为可能以其13.4倍市盈率避开的股票。尽管如此,我们需要更深入地挖掘以确定市盈率上升是否有合理的基础。
最近令康基医疗控股感到高兴,因为尽管市场收益出现逆转,但其收益却有所增加。市盈率可能很高,因为投资者认为该公司将继续比大多数人更好地应对更广泛的市场阻力。如果不是,那么现有股东可能会对股价的可行性有些紧张。
查看我们对康基医疗控股的最新分析

增长与高市盈率相匹配吗?
为了证明其市盈率是合理的,康基医疗控股需要在超过市场的情况下实现可观的增长。
首先回顾一下,我们发现该公司去年的每股收益增长了令人印象深刻的43%。在短期表现的推动下,最近三年期间,每股收益总体增长了98%。因此,股东们可能会对这些中期收益增长率表示欢迎。
展望来看,根据关注该公司的双重分析师的估计,未来三年将实现每年8.9%的增长。同时,预计其他市场每年将增长16%,这明显更具吸引力。
有鉴于此,令人震惊的是,康基医疗控股的市盈率高于其他大多数公司。显然,该公司的许多投资者比分析师所表示的要看涨得多,他们不愿意以任何价格抛售股票。如果市盈率降至更符合增长前景的水平,这些股东很有可能为未来的失望做好准备。
康基医疗控股市盈率的底线
通常,在做出投资决策时,我们会谨慎行事,不要过多地阅读市盈率,尽管这可以充分揭示其他市场参与者对公司的看法。
我们对康基医疗控股分析师预测的审查显示,其较差的盈利前景对其高市盈率的影响没有我们预期的那么大。当我们看到疲软的盈利前景且低于市场增长速度时,我们怀疑股价有下跌的风险,导致高市盈率走低。这使股东的投资面临重大风险,潜在投资者面临支付过高溢价的危险。
别忘了可能还有其他风险。例如,我们已经确定了康基医疗控股的一个警告信号,你应该注意这一点。
如果你对市盈率感兴趣,你可能希望看到这批盈利增长强劲、市盈率低的免费公司。
对这篇文章有反馈吗?对内容感到担忧?直接联系我们。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St的这篇文章本质上是笼统的。我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感型公司公告或定性材料。简而言之,华尔街没有持有任何上述股票的头寸。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Moomoo Securities Australia Limited提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Moomoo Securities Australia Limited, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Moomoo Securities Australia Limited提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Moomoo Securities Australia Limited, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧
